Previous studies from our group show the benefit of an infection-permissive preclinical vaccine strategy, which allows for the development of cross-protective CD8+ cellular-mediated responses directed towards the internal nucleoprotein.16 In the present study, some mouse groups vaccinated with the CBC-designed NAs are 100% protected against lethality, although some mice displayed significant signs of morbidity. Here, CD8A is linked to infection.